JUNB and chronic myelogenous leukemia, BCR-ABL1 positive: used JunB as a detection index to evaluate the efficacy of CML patients after receiving imatinib treatment, and found that increased expression of JunB combined with decreased expression of BCR-ABL is a good predictor of clinical prognosis in patients with CML after receiving imatinib treatment (Liu et al., 2006).